tiprankstipranks
Advertisement
Advertisement
TG Therapeutics reports positive Phase 3 ENHANCE trial results
PremiumCompany AnnouncementsTG Therapeutics reports positive Phase 3 ENHANCE trial results
10d ago
Morning Movers: Dycom skyrockets after first quarter results
Premium
The Fly
Morning Movers: Dycom skyrockets after first quarter results
10d ago
TG Therapeutics reports ENHANCE trial meets primary endpoint
Premium
The Fly
TG Therapeutics reports ENHANCE trial meets primary endpoint
10d ago
TG Therapeutics completes enrollment in Briumvi trial
PremiumThe FlyTG Therapeutics completes enrollment in Briumvi trial
2M ago
TG Therapeutics Files Procedural 8-K on Financial Obligation
Premium
Company Announcements
TG Therapeutics Files Procedural 8-K on Financial Obligation
3M ago
TG Therapeutics secures additional $500M in non-dilutive capital
Premium
The Fly
TG Therapeutics secures additional $500M in non-dilutive capital
3M ago
TG Therapeutics Confronts Rising AI Regulatory and IP Risks That Could Pressure Costs, Strategy, and Growth
PremiumCompany AnnouncementsTG Therapeutics Confronts Rising AI Regulatory and IP Risks That Could Pressure Costs, Strategy, and Growth
3M ago
Buy Rating Backed by Briumvi’s Strong Commercial Ramp, Growing CD20 Market Share, and Visible Long‑Term Revenue Expansion
Premium
Ratings
Buy Rating Backed by Briumvi’s Strong Commercial Ramp, Growing CD20 Market Share, and Visible Long‑Term Revenue Expansion
3M ago
TG Therapeutics sees FY26 revenue $875M-$900M, consensus $897.64M
Premium
The Fly
TG Therapeutics sees FY26 revenue $875M-$900M, consensus $897.64M
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100